Day: November 10, 2022

Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

– End of third quarter cash position of $90.7 million excludes the recent $50 million registered offering, and together, provide a cash runway into 2025 – – Phase 3 pivotal MANTRA trial topline data now anticipated in first quarter of 2023 – – Phase 2 MANTRA-2 trial preliminary interim data demonstrates encouraging monotherapy signal in ten evaluable patients; MANTRA-2 continues to enroll – – Phase 2 MANTRA-3 trial deprioritized to rationalize use of financial resources – – Phase 1/2 MANTRA-4 trial anticipated to commence in first quarter 2023 – – Management to host conference call and webcast today at 5:00 PM Eastern Time – NEWARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate,...

HTG Molecular Diagnostics Reports Third Quarter 2022 Results

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

TUCSON, Ariz., Nov. 10, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today reported financial results for the quarter ended September 30, 2022 and provided recent business highlights. “We are delighted with the continued and rapid progress we have made this past quarter in our effort to reposition HTG as a platform-based drug discovery company. Our strategy is to build best-in-class drug candidates for known targets with high unmet medical needs. We have achieved our third quarter 2022 milestones and remain on track to begin partnering conversations for our first target and indication by the end of 2022,” said John Lubniewski, Chief Executive Officer...

Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

Announced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to gain alignment on regulatory path forward as a drug/device combination product Company to host conference call and webcast today, November 10, at 4:30 pm ET NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced its financial and operating results for the third quarter ended September 30, 2022. Third Quarter 2022 and Recent Business DevelopmentsAnnounced that in a modified per-protocol analysis...

Venus Concept Announces Third Quarter of Fiscal Year 2022 Financial Results

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2022. Third Quarter 2022 Summary & Operating Highlights:Total revenue of $21.5 million, down $3.0 million, or 12%, year-over-year.U.S. revenue down 4% year-over-year. Cash system revenue up 30% year-over-year, representing approximately 59% of total systems and subscriptions revenue, compared to 39% in the prior year period.GAAP net loss attributable to stockholders of $14.6 million, compared to GAAP net loss attributable to stockholders of $9.8 million last year. Adjusted EBITDA loss of $7.7 million, compared to Adjusted EBITDA loss of $3.5 million last year. On October 3, 2022, the...

Urbana Corporation Has Filed 2022 Third Quarter Interim Financial Statements

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) — Urbana Corporation (TSX & CSE: URB & URB.A) announces today that it has filed its unaudited interim financial statements and management’s discussion and analysis for the nine-month period ended September 30, 2022 with the applicable Canadian securities regulators. PDF versions of the documents are available at www.urbanacorp.com and at www.sedar.com. For further information contact: Elizabeth Naumovski Investor Relations (416) 595-9106 enaumovski@urbanacorp.com

Farmers & Merchants Bancorp (OTCQX: FMCB) Announces Increase in the Year-End Cash Dividend

Written by Customer Service on November 10, 2022. Posted in Dividend Reports And Estimates.

LODI, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — The Board of Directors of Farmers & Merchants Bancorp (OTCQX: FMCB), a bank holding company headquartered in Lodi, California, declared a year-end cash dividend of $8.30 per share, an increase of 6.41% over the cash dividend declared in November of 2021. The cash dividend will be payable on January 3, 2023 to shareholders of record as of December 7, 2022. Total cash dividends declared in 2022 increased 5.56% to $16.15 per share compared with $15.30 declared in 2021. Based upon trailing twelve months net income of $90.70 per share, this represents a payout ratio of 18%. In addition, the Board of Directors made the decision to fulfill the Company’s $20 million repurchase plan in order to better optimize the Company’s capital structure. In the first nine months of 2022, the Company...

Stem Holdings Announces Offering

Written by Customer Service on November 10, 2022. Posted in Public Companies.

BOCA RATON, Fla., Nov. 10, 2022 (GLOBE NEWSWIRE) — Stem Holdings, Inc. (OTCQX: STMH) (CSE: STEM) (the “Company” or “Stem”), a vertically integrated cannabis operator, is pleased to announce that the Company intends to complete a private placement of a USD$250,000 unsecured promissory note (the “Note”) and 250,000 common share purchase warrants (the “Warrants”) to an arm’s length lender (the “Offering”). The Offering is expected to close on November 11, 2022. The Note terms provide for it to become due and payable in three months, subject to extension by the Company for an additional three months upon payment of a USD$5,000 extension fee to the lender. The Note bears interest at rate of 10% per annum payable at maturity. The Company may prepay the outstanding principal amount of the Note together with all accrued and unpaid interest,...

REVISED TIME – Canacol Energy Ltd. Will Hold Conference Call on Friday, November 11, 2022 at 11am ET

Written by Customer Service on November 10, 2022. Posted in Public Companies.

CALGARY, Alberta, Nov. 10, 2022 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) will announce its third quarter 2022 financial results on Thursday, November 10, 2022, after the market closure. Senior Management will hold a Conference Call to discuss results on Friday, November 11, 2022 at 9:00 a.m. MT / 11:00 a.m. ET, one hour later than previously announced. The conference call may be accessed by dial in or via webcast:Pre-register for the Conference Call: https://dpregister.com/sreg/10172053/f4c23d4c05Dial In Toll Free: 1-844-784-1724Participant International Dial In: 1-412-317-6716Canada Toll Free: 1-866-450-4696Colombia Toll Free: 01800-9-156803UK Toll Free: 08082389064Webcast link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=8QEAui2AAll...

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Written by Customer Service on November 10, 2022. Posted in Public Companies.

Poster #1: Tri-specific killer engagers target natural killer cells towards mesothelioma Poster #2: Enhancing NK cell function in the ‘cold’ tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA)BRISBANE, CALIFORNIA, Nov. 10, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, will present two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022. The two posters highlight tri-specific killer engagers for the treatment...

Correction: BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

Written by Customer Service on November 10, 2022. Posted in Public Companies.

November 10, 2022 Announcement no. 16 BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration COPENHAGEN, DENMARK and BOSTON, MA, USA, November 10, 2022, (GLOBE NEWSWIRE) — BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) has announced the submission of a De Novo application to the US Food and Drug Administration (FDA) of a neutrophil gelatinase-associated lipocalin (NGAL) test to aid in identifying pediatric patients (≥3 months to

Day: November 10, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice